腹部大動脈瘤および末梢動脈疾患における血管機能検査指標の検討

1) 2010 年度合同研究班報告. 大動脈瘤・大動脈解離診療ガイドライン（2011 年改

訂版）

2) Singh K, Bønaa H, Jacobsen B.K et al : Prevalence of and risk factors for

abdominal aortic aneurysms in a population-based study : The Tromso Study.

Am J Epidemiol, 2001;154:236-244

3) Powell JT, Greenhalgh RM: Clinical practice. Small abdominal aortic

aneurysms. N Engl J Med 2003;348:1895-1901

4) Brewster DC, Cronenwett JL, Hallett JW et al: Guidelines for the treatment

of abdominal aortic aneurysms. Report of a subcommittee of the Joint

Council of the American Association for Vascular Surgery and Society for

Vascular Surgery. J Vasc Surg 2003;37:1106-1117

5) Courtney J. Warner, Steven C. Stain, R. Clement Darling III: Should the

Management of a Ruptured Abdominal Aortic Aneurysm Be Regionalized?.

Advances in Surgery 2018;52:127-135

6) Harris LM, Faggioli GL, Fiedler R et al: Ruptured abdominal aortic

aneurysms: factors affecting mortality rates. J Vasc Surg 1991;14:812-820

7) Johnston KW: Ruptured abdominal aortic aneurysm: six-year follow-up

results of a multicenter prospective study. Canadian Society for Vascular

Surgery Aneurysm Study Group. J Vasc Surg 1994;19:888-900

8) Vardulaki KA, Prevost TC, Walker NM et al: Growth rates and risk of

rupture of abdominal aortic aneurysms. Br J Surg 1998;85:1674-1680

27

9) 2014 年度合同研究班報告. 末梢閉塞性動脈疾患の治療ガイドライン（2015 年

改訂版）

10) Bhatt DL, Steg PG, Ohman EM et al: International prevalence, recognition,

and

treatment

of

cardiovascular

risk

factorsin

outpatients

with

atherothrombosis.JAMA. 2006;295:180-189

11) Steg PG, Bhatt DL, Wilson PW, et al: One-year cardiovascular event ratesin

outpatients with atherothrombosis. JAMA. 2007;297:1197-1206

12) Akamatsu D, Sato A, Hitoshi G et al: Nitroglycerin-mediated vasodilatation

of the brachial artery may predict long-term cardiovascular events

irrespective of the presence of atherosclerotic disease. J Atheroscler Thromb,

2010;17:1266-74

13) Yeboah J, Crouse JR Hsu F et al. Brachial flow-mediated dilation predicts

incident cardiovascular events in older adults: the Cardiovascular Health

Study. Circulation 2007;115:2390-2397

14) Yeboah J, Folsom AR Burke GL et al. Predictive value of brachial

flow-mediated

dilation

population-based

study:

for

the

incident

cardiovascular

multi-ethnic

study

of

events

in

a

atherosclerosis.

Circulation 2009;120:502-509

15) Shimbo D, Grahame-Clarke C, Miyake Y et al.

The association between

endothelial dysfunction and cardiovascular outcomes in a population-based

multi-ethnic cohort. Atherosclerosis 2007;192:197-203

16) 2011-2012 年合同研究班報告.血管機能の非侵襲的評価法に関するガイドライン

17) Lee R, Bellamkonda K, Jones A et al: Flow Mediated Dilatation and

Progression of Abdominal Aortic Aneurysms. Eur J Vasc Endovasc

28

Surg,2017;53:820-829

18) Joaquin de Haro Miralles, Esther Marti´nez-Aguilar, Aurora Florez et al:

Nitric oxide: link between endothelial dysfunction and inflammation in

patients with peripheral arterial disease of the lower limbs. Interact

Cardiovasc Thorac Surg. 2009 Jul;9(1):107-12.

19) Brevetti G, Silvestro A, Schiano V et al: Endothelial dysfunction and

cardiovascular risk prediction in peripheral arterial disease: additive value

of flow-mediated dilation to ankle-brachial pressure index. Circulation,

2003,108:2093-2098

20) Gokce N, Keaney JF, Hunter LM et al: Predictive value of noninvasively

determined endothelial dysfunction for long-term cardiovascular events in

patients

with

peripheral

vascular

disease.

J

Am

Coll

Cardiol

2003;41:1769-1775

21) Chan SY, Mancini GB, Kuramoto L et al: The prognostic importance of

endothelial dysfunction and carotid atheroma burden in patients with

coronary artery disease. J Am Coll Cardiol 2003;42:1037-1043

22) Karatzis EN, Ikonomidis I, Vamvakou GD et al: Long-term prognostic role of

flow-mediated dilatation of the brachial artery after acute coronary

syndromes without ST elevation. Am J Cardiol 2006;98:1424-1428

23) Meyer B, Mortl D, Strecker K et al. Flow-mediated vasodilation predicts

outcome in patients with chronic heart failure: comparison with B-type

natriuretic peptide. J Am Coll Cardiol 2005; 46: 1011-1018

24) Fischer D, Rossa S, Landmesser U et al: Endothelial dysfunction in patients

with chronic heart failure is independently associated with increased

29

incidence of hospitalization, cardiac transplantation, or death. Eur Heart J

2005;26:65-69

25) Muiesan ML, Salvetti M, Paini A et al. Prognostic role of flow-mediated

dilatation of the brachial artery in hypertensive patients. J Hypertens

2008;26:1612-1618

26) Xu JZ, Zhang Y, Wu SN et al. Impaired endothelial function in hypertensive

patients with target organ damage. J Hum Hypertens 2009;23:751-757

27) Halcox JP, Donald AE, Ellins E et al: Endothelial function predicts

progression

of

carotid

intima-media

thickness.

Circulation

2009;119:1005-1012.

28) Iiyama K, Nagano M, Yo Y et al: Impaired endothelial function with

essential

hypertension

assessed

by

ultrasonography.

Am

Heart

J

1996;132:779-782

29) Drexler H, Hornig B: Endothelial dysfunction in human disease. J Mol Cell

Cardiol 1999;31:51-60

30) Adamopoulos S, Parissis JT, Kremastionos DT: Endothelial dysfunction in

chronic heart failure: clinical and therapeutic implications. Eur J Intern

Med 2002;13:233-239

31) Colombo PC, Banchs JE, Celaj S et al: Endothelial cell activation in patients

with decompensated heart failure. Circulation 2005;111:58-62

32) Kubo SH, Rector TS, Bank AJ, et al: Endothelium-dependent vasodilation is

attenuated in patients with heart failure. Circulation 1991;84:1589-1596

33) Vogel RA, Corretti MC: Estrogens, progestins, and heart disease: can

endothelial function divine the benefit? Circulation. 1998;97:1223-1226

30

34) CraiemD, Chironi G, Gariepy J et al: New monitoring software for larger

clinical

application

of

brachial

artery

flowmediated

vasodilatation

measurements. J Hypertens 2007;25:133-140

35) Kabutoya T, Hoshide S, Ogata Y et al：The time course of flow-mediated

vasodilation and endothelial dysfunction in patients with a cardiovascular

risk factor. J Am Soc Hypertens 2012;6(2):109-116

36) Chironi G, Craiem D, Miranda-Lacet J et al. Impact of shear stimulus, risk

factor burden and early atherosclerosis on the time-course of brachial artery

flow-mediated vasodilation. n. J Hypertens 2008;26(3):508-515

37) Tomiyama H, Matsumoto C Yamada J et al: The relationships of

cardiovascular disease risk factors to flow-mediated dilatation in Japanese

subjects free of cardiovascular disease. Hypertens Res, 2008;31:2019-2025

38) Witte DR, Westerink J Koning EJ et al: Is the association between

flow-mediated dilation and cardiovascular risk limited to low-risk

populations? J Am Coll Cardiol,2005;45:1987-1993

39) Donald AE, Halcox JP Charakida M et al: Methodological Approaches to

Optimize Reproducibility and Power in Clinical Studies of Flow-Mediated

Dilation. Journal of the American College of Cardiology 2008;51;20:

1959-1964.

40) Hashimoto

M,

Akishita

M,

Eto

M

et

al:

Modulation

of

endothelium-dependent flow-mediated dilatation of the brachial artery by

sex and menstrual cycle. Circulation 1995;92(12):3431-3435.

41) Lieberman EH, Gerhard MD, Uehata A et al: Estrogen improves

endothelium-dependent, flow-mediated vasodilation in postmenopausal

31

women. Ann Intern Med 1994;121(12):936-941

42) Mark A. Black, N. Timothy Cable, Dick H.J. Thijssen et al: Importance of

measuring the time course of flow-mediated dilatation in humans.

Hypertension 2007;51:203-10

43) Moxon JV, Parr A, Emeto TI et al: Diagnosis and monitoring of abdominal

aortic aneurysm: current status and future prospects. Curr Probl Cardiol

2010;35:512-48

44) Hamel MB, Henderson WG, Khuri SF et al. Surgical outcomes for patients

aged 80 and older: morbidity and mortality from major noncardiac surgery. J

Am Geriatr Soc 2005;53:424-9

45) Hicks CW, Obeid T, Arhuidese I et al. Abdominal aortic aneurysm repair in

octogenarians

is

associated

with

higher

mortality

compared

with

nonoctogenarians. J Vasc Surg 2016;64(4):956-965

46) Ihara M Urata H, Kinoshita A et al : Increased chymase-dependent

an-giotensin II formation in human atherosclerotic aorta. Hypertension

1999;33:1399-1405

47) Nishimoto M, Takai S, Fukumoto H et al : Increased local angiotensin II

formation in aneurysmal aorta. Life Sci 2002;71:2195-2205

48) Tsuruda T, Kato J, Hatakeyama K et al: Adventitial mast cells contribute to

pathogenesis in the progression of abdominal aortic aneurysm. Circ Res

2008;102:1368-1377

49) Millonig G, Malcom GT, Wick G et al: Early inflammatory-immunological

lesions in juvenile atherosclerosis from the Pathobiological Determinants of

Athero sclerosis in Youth(PDAY)- study. Atherosclerosis 2002;160:441-448

32

50) Curci JA, Thompson RW : Adaptive cellular immunity in aortic aneurysms :

cause, consequence, or context? .J Clin Invest 2004;114:168-171

51) Guo DC, Papke CL, He R et al : Pathogenesis of thoracic and abdominal

aortic aneurysms. Ann N Y Acad Sci 2006;1085:339-352

52) Ter Avest E, Stalenhoef AF, de Graaf J: What is the role of non-invasive

measurements

of

atherosclerosis

in

individual

cardiovascular

risk

prediction? Clin Sci (Lond) 2007;112:507-516

53) Goodman MN: Interleukin-6 induces skeletal muscle protein breakdown in

rats. Proc Soc Exp Biol Med 1994;205:182-5

54) Brevetti G, Schiano V, Chiariello M: Endothelial dysfunction: a key to the

pathophysiology and natural history of peripheral arterial disease?

Atherosclerosis 2008;197:1-11

55) Sanada H, Higashi Y, Goto C et al: Vascular function in patients with

peripheral arterial disease: a comparison of upper and lower extremities.

Atherosclerosis, 2005;178:179–185

56) Higashi Y, Sasaki S, Nakagawa K et al: Endothelial function and oxidative

stress in renovascular hypertension. N Engl J Med, 2002;346:1954-1962

57) Anderson JD, Epstein FH, Meyer CH et al: Multifactorial determinants of

functional capacity in peripheral arterial disease: uncoupling of calf muscle

perfusion and metabolism. J Am Coll Cardiol 2009;54:628-35

58) Brass EP, Hiatt WR: Acquired skeletal muscle metabolic myopathy in

atherosclerotic peripheral arterial disease. Vasc Med 2000;5:55-9

59) Ryan AS, Katzel LI, Gardner AW et al: Determinants of peak Vo2 in

peripheral arterial occlusive disease patients. J Gerontol A Biol Sci Med Sci

33

2000;55:B302-6

60) Charters Y, Grimble RF: Effect of recombinant human tumour necrosis

factor alpha on protein synthesis in liver, skeletal muscle and skin of rats.

Biochem J 1989;258:493-7

61) Higashi Y, Yoshizumi M: Exercise and endothelial function: role of

endothelium-derived nitric oxide and oxidative stress in healthy subjects

and hypertensive patients (review). Pharmacol Ther, 2004;102:87-96

62) McIntyre M, Bohr DF, Dominiczak AF: Endothelial function in hypertension:

the role of superoxide anion. Hypertension, 1999;34:539-545

63) Taddei S, Virdis A, Ghiadoni L et al: Age-related reduction of NO availability

and oxidative stress in humans. Hypertension 2001;38:274-279.

34

Ⅹ. 図表の説明、図

図 1. 血管機能検査における B モードおよび A モードの対比

血管径測定画面は B モードの短軸および長軸像と、超音波の振幅と距離を表す一次

情報であり、B モード画像の 5 倍の分解能を持つ A モード波形が表示されている。A

モードから輝度変換を行って B モード表示が行われ、B モード画像に加工する前段階

で高い分解能を有する A モード信号で血管径の計測を行う。A モード中央の黄色のバ

ーは、上端が体表側の内皮(near wall)、下端が深部側の内皮(far wall)を示す。長軸像

の中央の黄色のバーと A モードの中央の黄色のバーは同一である。

図 2. 経時的曲線上で表した各指標

拡張開始時間：駆血開放あるいは投薬後に血管径が変化し始めるまでの時間、拡張

時間：拡張開始から最大拡張時径までの時間を示す時間、血流減衰時定数：駆血開放

後に血流速度や血流量が一時的に増大し減少する過程での血流量、AUC：拡張開始か

ら最大拡張時径までの曲線得られる積分値である拡張曲線下面積、拡張最大速度：血

管径が拡張する連続測定の過程で最大の血流速度、拡張時定数：拡張開始から最大拡

張時径の 63％の径に達する時間を示す時定数

図 3. AAA 群における瘤径別⊿FMD/⊿NMD および FMD/NMD-AUC

35

図 4. PAD 群における Fontaine 分類別⊿FMD/⊿NMD および FMD/NMD-AUC

図 5.

AAA 群における糖尿病または脂質異常症の有無での FMD-AUC の比較

図 6.

PAD 群における糖尿病または脂質異常症の有無での FMD-AUC の比較

図 7.

血管機能検査における評価対象

36

図１. 血管機能検査における B モードおよび A モードの対比

37

図２. 経時的曲線上で表した各指標

38

図３. AAA 群における瘤径別⊿FMD/⊿NMD および FMD/NMD-AUC

39

図４. PAD 群における Fontaine 分類別⊿FMD/⊿NMD および FMD/NMD-AUC

40

図５. AAA 群における糖尿病または脂質異常症の有無での FMD-AUC の比較

41

図６. PAD 群における糖尿病または脂質異常症の有無での FMD-AUC の比較

42

図７. 血管機能検査における評価対象

43

Ⅺ. 表

表 1．AAA 群における瘤径分類別の患者特性

n.s.: not significant

BMI：body mass index

packyear：(１日の喫煙本数 / 20 本) × 喫煙年数

SBP：systolic blood pressure

DBP：diastolic blood pressure

T-cho：total cholesterol

HDL：high density lipoprotein

LDL：low density lipoprotein

TG：triglycerides

HbA1c：glycated haemoglobin

eGFR：estimated glomerular filtration rate

ARB：angiotensin II receptor blocker

ACE：Angiotensin converting enzyme

NO：nitric oxide

CRP：C-reactive protein

44

表２. AAA 群における瘤径分類別の FMD ならびに NMD

*：p<0.05

45

表３. PAD 群における Fontaine 分類別の患者特性

n.s.: not significant

BMI：body mass index

packyear：(１日の喫煙本数 / 20 本) × 喫煙年数

SBP：systolic blood pressure

DBP：diastolic blood pressure

T-cho：total cholesterol

HDL：high density lipoprotein

LDL：low density lipoprotein

TG：triglycerides

HbA1c：glycated haemoglobin

eGFR：estimated glomerular filtration rate

ARB：angiotensin II receptor blocker

ACE：angiotensin converting enzyme

NO：nitric oxide

CRP：C-reactive protein

46

表４. PAD 群における Fontaine 分類別の FMD ならびに NMD

*：p<0.05

47

表 5. PAD 群における Fontaine 分類別重症度と相関する因子

自由度調整済み決定係数 R2, FMD-AUC：0.226, NMD-AUC：0.311

48

...